公开(公告)号：US20240293513A1

公开(公告)日：2024-09-05

申请号：US18573602

申请日：2022-06-23

申请人： INNOVENT BIOLOGICS (SUZHOU) CO., LTD.

发明人： Pei AN ,  Huan DENG

IPC分类号： A61K38/26 ,  A61K47/18 ,  A61K47/26 ,  A61P19/06

CPC分类号： A61K38/26 ,  A61K47/18 ,  A61K47/26 ,  A61P19/06

摘要： The present invention discloses use of mazdutide, more particularly, use of a compound of formula (I) in preparing a medicament for reducing a uric acid level in a patient. Formula (I) is shown in the specification. Mazdutide of the present invention has a significant effect of reducing uric acid.

公开(公告)号：US20240116873A1

公开(公告)日：2024-04-11

申请号：US18514302

申请日：2023-11-20

申请人： JIANGSU CHIATAI QINGJIANG PHARMACEUTICAL CO., LTD.

发明人： Jie CHEN ,  Jun Lu ,  Fujia XIE ,  Lv HUANG

IPC分类号： C07D215/36 ,  A61P19/06 ,  C07D409/12

CPC分类号： C07D215/36 ,  A61P19/06 ,  C07D409/12

摘要： A quinoline mercaptoacetate sulfonamide derivative, an intermediate, a pharmaceutical derivative or a formulation, and a preparation method and use therefor, wherein the structure of the quinoline mercaptoacetate sulfonamide derivative is as represented by the following formula (I). A preparation method for a compound containing a structure is also represented by the following formula. Experiments show that the compound has a good inhibitory effect on URAT1 transport uric acid in HEK293 transfected cells, and that the compound has good application prospects in the treatment of hyperuricemia or gout.

公开(公告)号：US20190225606A1

公开(公告)日：2019-07-25

申请号：US16313149

申请日：2016-09-02

申请人： SHANDONG UNIVERSITY

发明人： Xinyong LIU ,  Qing MENG ,  Peng ZHAN ,  Zengjun FANG ,  Tong ZHAO ,  Zhuosen SUN ,  Xiukun SUN

IPC分类号： C07D471/04 ,  A61P19/06

CPC分类号： C07D471/04 ,  A61K31/437 ,  A61P19/06

摘要： It relates to the imidazopyridine thioglycolic acid derivatives, the preparation, and use thereof. The invention contained imidazopyridine thioglycolic acid derivatives with the formula I or II or III. Also described here are preparation of imidazopyridine thioglycolic acid derivatives, pharmaceutical compositions comprising these compounds as therapy and prevention for gout.

公开(公告)号：US20180148455A1

公开(公告)日：2018-05-31

申请号：US15578086

申请日：2015-12-23

申请人： AJOU UNIVERSITY INDUSTRY-ACADEMIC COOPERATION FOUNDATION

发明人： Sang Dun CHOI ,  Prasannavenkatesh DURAI ,  Asma ACHEK

IPC分类号： C07D487/04 ,  C07D409/12 ,  C07D211/26 ,  C07D243/08 ,  C07C251/24 ,  C07D265/30 ,  C07D401/12 ,  C07D471/10 ,  C07D211/34 ,  C07D401/14 ,  C07D403/06 ,  C07D403/12 ,  C07D401/06 ,  C07D333/78 ,  C07D207/277 ,  C07D471/04 ,  A61P7/00 ,  A61P17/00 ,  A61P37/08 ,  A61P11/06 ,  A61P27/02 ,  A61P1/02 ,  A61P27/00 ,  A61P27/16 ,  A61P1/00 ,  A61P31/12 ,  A61P11/00 ,  A61P1/04 ,  A61P19/06 ,  A61P19/02 ,  A61P29/00 ,  A61P13/12 ,  A61P25/28

CPC分类号： C07D487/04 ,  A61K9/0053 ,  A61K31/4178 ,  A61K31/4453 ,  A61K31/496 ,  A61K31/506 ,  A61K31/5377 ,  A61K31/551 ,  A61P1/00 ,  A61P1/02 ,  A61P1/04 ,  A61P7/00 ,  A61P11/00 ,  A61P11/06 ,  A61P13/12 ,  A61P17/00 ,  A61P19/02 ,  A61P19/06 ,  A61P25/28 ,  A61P27/00 ,  A61P27/02 ,  A61P27/16 ,  A61P29/00 ,  A61P31/12 ,  A61P37/08 ,  C07C251/24 ,  C07D207/277 ,  C07D211/26 ,  C07D211/34 ,  C07D243/08 ,  C07D265/30 ,  C07D333/78 ,  C07D401/06 ,  C07D401/12 ,  C07D401/14 ,  C07D403/06 ,  C07D403/12 ,  C07D409/12 ,  C07D471/04 ,  C07D471/10

摘要： The present disclosure relates to a novel small molecule TLR2 antagonist, and particularly, to 19 novel TLR2 antagonists, a pharmaceutical composition, including the antagonists, for preventing or treating inflammatory diseases, and a TLR4 regulator.The novel TLR2 antagonists according to the present disclosure can be effectively used as a preparation for oral administration by having low molecular weight and high oral bioavailability, and can be useful in pharmaceutical compositions for preventing or treating inflammatory diseases since the secretion of IL-8 is effectively inhibited and in vivo cytotoxicity is not induced. In addition, the novel TLR2 antagonists according to the present disclosure can be used as a TLR4 regulator.

公开(公告)号：US20240335395A1

公开(公告)日：2024-10-10

申请号：US18578957

申请日：2022-07-15

申请人： ALLSPIM

发明人： Jean-Marie ANDRIEU ,  Louis LU

IPC分类号： A61K31/12 ,  A61P15/08 ,  A61P17/06 ,  A61P19/02 ,  A61P19/06 ,  A61P21/00 ,  A61P27/02 ,  A61P29/00 ,  A61P37/06

CPC分类号： A61K31/12 ,  A61P15/08 ,  A61P17/06 ,  A61P19/02 ,  A61P19/06 ,  A61P21/00 ,  A61P27/02 ,  A61P29/00 ,  A61P37/06

摘要： The present invention relates to compositions comprising 2′,4′-dihydroxy-3′,6′-dimethoxychalcone or a pharmaceutically acceptable salt thereof for use as a medicament. In particular, the present invention relates to compositions comprising 2′,4′-dihydroxy-3′,6′-dimethoxychalcone or a pharmaceutically acceptable salt thereof for use in the prevention and/or treatment of a disease associated with IL-23/IL-17 axis activation, except cancers.

公开(公告)号：US11865147B2

公开(公告)日：2024-01-09

申请号：US17457758

申请日：2021-12-06

申请人： GLAC BIOTECH CO., LTD.

发明人： Hsieh-Hsun Ho ,  Ching-Wei Chen ,  Yi-Wei Kuo ,  Jui-Fen Chen

IPC分类号： A61K35/747 ,  A61P19/06 ,  C12N1/20 ,  C12P1/04 ,  A23L33/135 ,  A23L33/00 ,  C12R1/25

CPC分类号： A61K35/747 ,  A23L33/135 ,  A23L33/40 ,  A61P19/06 ,  C12N1/205 ,  C12P1/04 ,  A23V2002/00 ,  A23V2400/143 ,  A23V2400/169 ,  A23V2400/173 ,  C12R2001/25

摘要： Disclosed herein are methods for reducing purine content in an edible material and alleviating a disorder of uric acid metabolism using Lactobacillus plantarum TSP05 which is deposited at the China General Microbiological Culture Collection Center (CGMCC) under an accession number CGMCC 16710.

公开(公告)号：US20230381254A1

公开(公告)日：2023-11-30

申请号：US18335248

申请日：2023-06-15

申请人： Jiangnan University

发明人： Gang WANG ,  Caixin NI ,  Yuxing ZHENG ,  Linlin WANG ,  Jianxin ZHAO ,  Hao ZHANG ,  Wei CHEN

IPC分类号： A61K35/747 ,  C12N1/20 ,  A61P19/06

CPC分类号： A61K35/747 ,  C12N1/205 ,  A61P19/06

摘要： The present disclosure discloses Lactobacillus reuteri CCFM1132 capable of relieving hyperuricemia and application thereof, which belongs to the technical field of microorganisms. The L. reuteri CCFM1132 can reduce serum uric acid levels of mice with hyperuricemia, inhibit the activity of serum and liver xanthine oxidase (XOD), and reduce the occurrence of hyperuricemia and gout; reduce serum creatinine levels, reduce serum total triglyceride (TG) levels, and inhibit the activity of serum alkaline phosphatase (ALP); and promote the expression of ileum uric acid transporter ABCG2. The L. reuteri CCFM1132 of the present disclosure can be used for preparing functional bacterial agents, food and medicines for relieving hyperuricemia and gout, and has a wide application prospect.

公开(公告)号：US20230330041A1

公开(公告)日：2023-10-19

申请号：US18043068

申请日：2021-08-20

申请人： BEIJING CHANGSHENG PHARMACEUTICAL TECHNOLOGY CO., LTD.

发明人： Guowen LI ,  Xianhua CHEN

IPC分类号： A61K31/133 ,  A61P19/06

CPC分类号： A61K31/133 ,  A61P19/06

摘要： A use of a tris (hydroxymethyl) aminomethane pharmaceutically acceptable salt or a composition formed by tris (hydroxymethyl) aminomethane and an inorganic acid or an organic acid in the preparation of drugs for treating or preventing hyperuricemia, gout, acute and chronic arthritis, gouty nephropathy, uric acid nephrolithiasis and related diseases. A use of tris (hydroxymethyl) aminomethane in the preparation of topical pharmaceutical compositions for preventing or treating gout and gouty arthritis by topical and transdermal administration.

公开(公告)号：US11679123B2

公开(公告)日：2023-06-20

申请号：US16978931

申请日：2019-03-07

申请人： Queen's University at Kingston ,  Jilin University

发明人： Yin Gao ,  Tassos Anastassiades

IPC分类号： A61K31/728 ,  A61P19/06 ,  A61P37/06

CPC分类号： A61K31/728 ,  A61P19/06 ,  A61P37/06

摘要： The invention provides a pharmaceutical composition of hyaluronic acid comprising repeating units of a disaccharide comprising glucuronic acid and N-acetylglucosamine, wherein a portion of the N-acetyl groups of the N-acetylglucosamine have been independently replaced with a group of the formula —N—C(O)—(C2-C4)-alkyl for treating hyperuicemia and gouty arthritis. Studies show that this composition is promising as an anti-gout therapeutic agent, which combines both anti-inflammatory actions as well as anti uracemic effects.

公开(公告)号：US20230173035A1

公开(公告)日：2023-06-08

申请号：US17955437

申请日：2022-09-28

申请人： Horizon Therapeutics USA, Inc.

发明人： Jeffrey D. KENT ,  Brian LAMOREAUX ,  John BOTSON ,  Jeff PETERSON

IPC分类号： A61K38/44 ,  A61K47/34 ,  A61P19/06 ,  A61K31/519

CPC分类号： A61K38/44 ,  A61K47/34 ,  A61P19/06 ,  A61K31/519

摘要： The disclosure provides methods of treating gout in patients comprising administering a PEGylated uricase. Also provided are methods of treating gout in patients comprising co-administering a PEGylated uricase and methotrexate (MTX). Also provided are methods of reducing immunogenicity of a PEGylated uricase and prolonging the urate lowering effect comprising co-administration of the PEGylated uricase and MTX.